

ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/

Form 8-K

February 27, 2004

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 25, 2004

### **Arrhythmia Research Technology, Inc.**

*(Exact name of issuer as specified in its charter)*

Delaware  
*(State or other jurisdiction of  
Incorporation or organization)*

1-9731  
*(Commission File Number)*

72-0925679  
*(I.R.S. Employer Identification Number)*

25 Sawyer Passway  
Fitchburg, MA 01420

*(Address of principal executive offices and zip code)*

**(978) 345-5000**

*(Registrant's telephone number, including area code)*

---

## **Item 5. Other Events and Regulation FD Disclosures**

On February 25, 2004 the Board of Directors of Arrhythmia Research Technology, Inc. (the Company) declared a cash dividend. The Company issued a press release dated February 25, 2004 announcing the cash dividend, which is attached as Exhibit 99.1 to this report.

## **Item 7. Financial Statements, Pro Forma Financial Information and Exhibits**

(c). Exhibits

<b><u>Exhibit Number</u></b>	<b><u>Description</u></b>
<u>99.1</u>	<u>Press Release dated February 25, 2004 announcing cash dividend.</u>
<u>99.2</u>	<u>Press Release dated February 25, 2004 announcing its financial results for the 4th quarter and year ended December 31, 2003.</u>

## **Item 12. Financial Statements**

On February 25, 2004, The Company issued a press release announcing its financial results for the 4<sup>th</sup> quarter and year ended December 31, 2003. The press release is attached as Exhibit 99.2 to this report.

The information set forth in this Item 12 and Exhibit 99.2 are furnished to, but shall not be deemed filed with the Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise incorporated by reference into any filing pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such a filing.

## **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fitchburg, Commonwealth of Massachusetts, on the 27<sup>th</sup> day of February 2004.

ARRHYTHMIA RESEARCH TECHNOLOGY, INC.

By: /s/ David A. Garrison  
David A. Garrison  
Chief Financial Officer

---

**Exhibit Index**

<b><u>Exhibit Number</u></b>	<b><u>Description</u></b>
<u>99.1</u>	<u>Press Release dated February 25, 2004 announcing cash dividend.</u>
<u>99.2</u>	<u>Press Release dated February 25, 2004 announcing its financial results for the 4th quarter and year ended December 31, 2003.</u>